

## NeoDynamics AB (publ) announces approval on passportation of prospectus

NeoDynamics AB (publ) ("NeoDynamics") – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – hereby announces approval on passportation of the prospectus.

NeoDynamics AB (publ) ("NeoDynamics") – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – hereby announces approval on passportation of the prospectus. The Swedish Financial Supervisory Authority has issued an approval on passportation of NeoDynamics' prospectus offering for subscription of units in Finland and Norway. The prospectus is available on the websites of the NeoDynamics ([www.neodynamics.com](http://www.neodynamics.com)) and Sedermera Fondkommission ([www.sedermera.se](http://www.sedermera.se)). The prospectus is also available at [www.spotlightstockmarket.com](http://www.spotlightstockmarket.com).

### Financial advisor

Sedermera Fondkommission is the financial advisor and Issuing Agent to NeoDynamics in connection with the issue of units and the planned listing on Spotlight. Nordnet Bank AB is acting as Selling Agent in the issue of units.

### For further information about the upcoming IPO and the planned listing, please contact:

Sedermera Fondkommission

Telephone: +46 (0) 40-615 14 10

E-mail: [info@sedermera.se](mailto:info@sedermera.se)

### For further information about NeoDynamics, please contact:

Anna Eriksrud, CEO NeoDynamics AB (publ)

Telephone: +46 8 522 79 667

E-mail: [anna.eriksrud@neodynamics.se](mailto:anna.eriksrud@neodynamics.se)

### About NeoDynamics AB (publ)

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.